MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462293 | Name: COR167
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

COR167 is a CB2 agonist. It displayed potent immunomodulatory activity on immune cells from healthy subjects and patients with multiple sclerosis. It also showed protective effects on rat brain tissues toward ischemia and reperfusion-induced injury. COR167 has antinociceptive properties.

Chemical Structure

COR167
CAS#1048038-90-9

Theoretical Analysis

MedKoo Cat#: 462293

Name: COR167

CAS#: 1048038-90-9

Chemical Formula: C28H38N2O2

Exact Mass: 434.2933

Molecular Weight: 434.62

Elemental Analysis: C, 77.38; H, 8.81; N, 6.45; O, 7.36

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 600.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
COR167; COR-167; COR 167; SER 601; SER601; SER-601
IUPAC/Chemical Name
N-(Adamant-1-yl)-6-isopropyl-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide
InChi Key
KUMKLUDNETVLDS-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H38N2O2/c1-4-5-6-9-30-17-24(26(31)23-13-22(18(2)3)7-8-25(23)30)27(32)29-28-14-19-10-20(15-28)12-21(11-19)16-28/h7-8,13,17-21H,4-6,9-12,14-16H2,1-3H3,(H,29,32)
SMILES Code
O=C(C4=CN(CCCCC)C5=C(C=C(C(C)C)C=C5)C4=O)NC12CC(C3)CC(CC3C2)C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
A selective CB2 receptor agonist.
In vitro activity:
COR167 was found to significantly reduce the proliferation of both glioblastoma and anaplastic astrocytoma in a dose-dependent manner at lower doses than other known, less specific CB2 agonists. Reference: Cent Nerv Syst Agents Med Chem. 2019;19(3):206-214. https://pubmed.ncbi.nlm.nih.gov/31549596/
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMF 5.0 11.50
Ethanol 3.0 6.90
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 434.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Cioni C, Tassi M, Marotta G, Mugnaini C, Corelli F, Annunziata P. A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors. Cent Nerv Syst Agents Med Chem. 2019;19(3):206-214. doi: 10.2174/1871524919666190923154351. PMID: 31549596. 2. Annunziata P, Cioni C, Mugnaini C, Corelli F. Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis. J Neuroimmunol. 2017 Feb 15;303:66-74. doi: 10.1016/j.jneuroim.2016.12.009. Epub 2016 Dec 23. PMID: 28041663.
In vitro protocol:
1. Cioni C, Tassi M, Marotta G, Mugnaini C, Corelli F, Annunziata P. A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors. Cent Nerv Syst Agents Med Chem. 2019;19(3):206-214. doi: 10.2174/1871524919666190923154351. PMID: 31549596. 2. Annunziata P, Cioni C, Mugnaini C, Corelli F. Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis. J Neuroimmunol. 2017 Feb 15;303:66-74. doi: 10.1016/j.jneuroim.2016.12.009. Epub 2016 Dec 23. PMID: 28041663.
In vivo protocol:
TBD
1: Pasquini S, Botta L, Semeraro T, et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J Med Chem. 2008;51(16):5075-5084. doi:10.1021/jm800552f 2: Contartese A, Valoti M, Corelli F, et al. A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury. Pharmacol Res. 2012;66(6):555-563. doi:10.1016/j.phrs.2012.08.003

View History

AS2541019

AS2541019

AS-1669058 free base

AS-1669058 free base

AS-0141 was removed

AS-0141 was removed